ARQT - Immunic Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Immunic announced positive top line data for IMU-838
Immunic Inc. (IMUX) announced top line data from Phase EMPhASIS trial of lead drug candidate, IMU-838, aimed at patients with relapsing-remitting multiple sclerosis or RRMS. The company reported that the trial achieved all its primary and secondary endpoints. The drug candidate was also observed to be well-tolerated and safe, in line with the prior data.
The phase 2 EMPhASIS trial was an international, multicenter, double-blind study. This randomized, placebo-controlled, parallel group study aims to evaluate the efficacy and safety of IMU-838 in patients with RRMS.